Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALC033
MIFTS: 58

Alcohol Use Disorder

Categories: Genetic diseases, Mental diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Alcohol Use Disorder

About this section

MalaCards integrated aliases for Alcohol Use Disorder:

Name: Alcohol Use Disorder 12 25 15
Alcohol Abuse 12 55 15
Alcoholism 25 44
Alcohol Dependence 25
Alcohol Addiction 25
Ethanol Abuse 12

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1574
ICD9CM 35 305.0 305.00
MeSH 44 D000437
NCIt 50 C20701
SNOMED-CT 68 15167005
ICD10 33 F10.1 Z72.1
UMLS 72 C0085762
Sources

Summaries for Alcohol Use Disorder

About this section
Genetics Home Reference : 25 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated. Alcohol use disorder is a broad diagnosis that encompasses several commonly used terms describing problems with drinking. It includes alcoholism, also called alcohol addiction, which is a long-lasting (chronic) condition characterized by a powerful, compulsive urge to drink alcohol and the inability to stop drinking after starting. In addition to alcoholism, alcohol use disorder includes alcohol abuse, which involves problem drinking without addiction. Habitual excessive use of alcohol changes the chemistry of the brain and leads to tolerance, which means that over time the amount of alcohol ingested needs to be increased to achieve the same effect. Long-term excessive use of alcohol may also produce dependence, which means that when people stop drinking, they have physical and psychological symptoms of withdrawal, such as sleep problems, irritability, jumpiness, shakiness, restlessness, headache, nausea, sweating, anxiety, and depression. In severe cases, agitation, fever, seizures, and hallucinations can occur; this pattern of severe withdrawal symptoms is called delirium tremens. The heavy drinking that often occurs in alcohol use disorder, and can also occur in short-term episodes called binge drinking, can lead to a life-threatening overdose known as alcohol poisoning. Alcohol poisoning occurs when a large quantity of alcohol consumed over a short time causes problems with breathing, heart rate, body temperature, and the gag reflex. Signs and symptoms can include vomiting, choking, confusion, slow or irregular breathing, pale or blue-tinged skin, seizures, a low body temperature, a toxic buildup of substances called ketones in the blood (alcoholic ketoacidosis), and passing out (unconsciousness). Coma, brain damage, and death can occur if alcohol poisoning is not treated immediately. Chronic heavy alcohol use can also cause long-term problems affecting many organs and systems of the body. These health problems include irreversible liver disease (cirrhosis), inflammation of the pancreas (pancreatitis), brain dysfunction (encephalopathy), nerve damage (neuropathy), high blood pressure (hypertension), stroke, weakening of the heart muscle (cardiomyopathy), irregular heartbeats (arrhythmia), and immune system problems. Long-term overuse of alcohol also increases the risk of certain cancers, including cancers of the mouth, throat, esophagus, liver, and breast. Alcohol use in pregnant women can cause birth defects and fetal alcohol syndrome, which can lead to lifelong physical and behavioral problems in the affected child.

MalaCards based summary : Alcohol Use Disorder, also known as alcohol abuse, is related to depression and mental depression. An important gene associated with Alcohol Use Disorder is ALDH2 (Aldehyde Dehydrogenase 2 Family Member), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are no effect and behavior/neurological

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Wikipedia : 75 Alcoholism, also known as alcohol use disorder (AUD), is a broad term for any drinking of alcohol that... more...

Sources

Related Diseases for Alcohol Use Disorder

About this section

Diseases in the Alcohol Use Disorder family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Use Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2190)
# Related Disease Score Top Affiliating Genes
1 depression 31.7 SLC6A4 HTR2A BDNF
2 mental depression 31.6 SLC6A4 HTR2A BDNF
3 anxiety 31.5 SLC6A4 HTR3A HTR2A BDNF
4 methanol poisoning 31.4 CYP2E1 ADH1C ADH1B
5 conduct disorder 31.4 SLC6A4 DRD2 ALDH2
6 post-traumatic stress disorder 31.1 SLC6A4 HTR2A DRD2 BDNF
7 borderline personality disorder 31.1 SLC6A4 HTR2A BDNF
8 social phobia 31.1 SLC6A4 HTR3A DRD2
9 bipolar disorder 31.0 SLC6A4 HTR2A DRD3 DRD2 BDNF
10 mood disorder 31.0 SLC6A4 HTR2A DRD3 DRD2 BDNF
11 antisocial personality disorder 31.0 SLC6A4 DRD2 ANKK1 ALDH2
12 eating disorder 31.0 SLC6A4 DRD2 BDNF
13 cocaine abuse 31.0 SLC6A4 HTR3A DRD2
14 panic disorder 31.0 SLC6A4 HTR3A HTR2A
15 fetal alcohol syndrome 30.9 GRIN2B ALDH2 ADH1B
16 personality disorder 30.9 SLC6A4 HTR2A DRD2 BDNF ANKK1 ALDH2
17 alexithymia 30.9 SLC6A4 DRD2 ANKK1
18 opiate dependence 30.9 SLC6A4 DRD3 DRD2
19 tobacco addiction 30.8 SLC6A4 HTR2A DRD2 ANKK1 ALDH2
20 substance dependence 30.7 SLC6A4 DRD3 DRD2 BDNF
21 generalized anxiety disorder 30.7 SLC6A4 HTR3A HTR2A DRD2 BDNF
22 bulimia nervosa 30.7 SLC6A4 HTR3A HTR2A BDNF
23 bipolar i disorder 30.7 SLC6A4 HTR2A DRD1 BDNF
24 paranoid schizophrenia 30.6 SLC6A4 HTR2A BDNF
25 endogenous depression 30.6 SLC6A4 HTR2A BDNF
26 autism spectrum disorder 30.6 SLC6A4 HTR2A GRIN2B BDNF
27 gilles de la tourette syndrome 30.5 HTR3A DRD2 BDNF
28 substance abuse 30.5 TF SLC6A4 GABRA2 DRD3 DRD2 BDNF
29 atypical depressive disorder 30.4 SLC6A4 HTR2A
30 alcoholic psychosis 30.4 SLC6A4 HTR2A DRD2
31 drug dependence 30.4 SLC6A4 DRD3 DRD2 BDNF ANKK1
32 pervasive developmental disorder 30.4 SLC6A4 GRM5 BDNF
33 periodic limb movement disorder 30.3 SLC6A4 HTR2A DRD2
34 polysubstance abuse 30.3 DRD3 DRD2
35 heroin dependence 30.3 DRD2 BDNF ANKK1
36 tardive dyskinesia 30.3 HTR2A DRD3 DRD2
37 alcoholic pancreatitis 30.3 CYP2E1 ALDH2 ADH1B
38 schizoaffective disorder 30.3 SLC6A4 HTR2A DRD3 DRD2 BDNF
39 anorexia nervosa 30.3 SLC6A4 HTR2A BDNF
40 bruxism 30.3 HTR2A DRD3 DRD2
41 migraine without aura 30.3 SLC6A4 DRD3 DRD2
42 impulse control disorder 30.3 DRD3 DRD2 ANKK1
43 alcohol-induced mental disorder 30.2 SLC6A4 DRD2
44 cocaine dependence 30.2 SLC6A4 DRD3 DRD2
45 fibromyalgia 30.2 SLC6A4 HTR3A HTR2A
46 serotonin syndrome 30.2 SLC6A4 HTR3A HTR2A
47 pathological gambling 30.2 SLC6A4 HTR2A DRD3 DRD2 DRD1
48 major depressive disorder 30.1 SLC6A4 HTR3A HTR2A GRM5 GRIN2B DRD3
49 delusional disorder 30.1 DRD3 DRD2
50 substance-induced psychosis 30.0 HTR2A DRD2

Graphical network of the top 20 diseases related to Alcohol Use Disorder:



Diseases related to Alcohol Use Disorder
Sources

Symptoms & Phenotypes for Alcohol Use Disorder

About this section

GenomeRNAi Phenotypes related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADH1B ADH1C ALDH2 ALDH9A1 ANKK1 BDNF

MGI Mouse Phenotypes related to Alcohol Use Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ALDH2 BDNF CYP2E1 DRD1 DRD2 DRD3
2 growth/size/body region MP:0005378 10.13 ADH1C ALDH2 BDNF DRD1 DRD2 DRD3
3 homeostasis/metabolism MP:0005376 10.1 ADH1C ALDH2 BDNF CYP2E1 DRD1 DRD2
4 integument MP:0010771 9.9 ALDH2 ALDH9A1 BDNF DRD1 DRD2 GABBR1
5 mortality/aging MP:0010768 9.8 ADH1C ALDH2 BDNF CYP2E1 DRD1 DRD2
6 nervous system MP:0003631 9.36 ALDH2 BDNF DRD1 DRD2 DRD3 GABBR1
Sources

Drugs & Therapeutics for Alcohol Use Disorder

About this section

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Disulfiram For the treatment and management of chronic alcoholism DB00822

Drugs for Alcohol Use Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 634)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
5
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
7
Nefopam Approved, Investigational Phase 4 13669-70-0
8
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
9
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
10
Insulin glargine Approved Phase 4 160337-95-1
11
Insulin Lispro Approved Phase 4 133107-64-9
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Losartan Approved Phase 4 114798-26-4 3961
14
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Pravastatin Approved Phase 4 81093-37-0 54687
17
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
18
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
19
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
20
Baclofen Approved Phase 4 1134-47-0 2284
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
23
Memantine Approved, Investigational Phase 4 19982-08-2 4054
24
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
25
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Cycloserine Approved Phase 4 68-41-7 6234 401
29
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
30
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
31
Oxazepam Approved Phase 4 604-75-1 4616
32
Sodium oxybate Approved Phase 4 502-85-2 5360545
33
Chlorzoxazone Approved Phase 4 95-25-0 2733
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
36
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
37
Ribavirin Approved Phase 4 36791-04-5 37542
38
Methadone Approved, Illicit Phase 4 76-99-3 4095
39
Haloperidol Approved Phase 4 52-86-8 3559
40
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
41
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
42
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
43
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
44
Simvastatin Approved Phase 4 79902-63-9 54454
45
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
46
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
47
Remifentanil Approved Phase 4 132875-61-7 60815
48
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
49
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
50
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825

Interventional clinical trials:

(show top 50) (show all 1546)
# Name Status NCT ID Phase Drugs
1 The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
2 Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study Unknown status NCT01135602 Phase 4 Topiramate
3 Double Blind Placebo Controlled Randomized Clinical Trial of Pregabalin for Alcohol Dependence Unknown status NCT02205879 Phase 4 Pregabalin;Placebo
4 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
5 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
6 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
7 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
8 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Unknown status NCT01967433 Phase 4 Diphenhydramine;Placebo
9 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
10 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4 antabuse (disulfiram)
11 Effect of a Treatment Switch From Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients. Unknown status NCT02691065 Phase 4 Integrase Inhibitor
12 A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS Unknown status NCT02126332 Phase 4
13 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
14 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
15 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
16 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
17 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
18 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
19 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
20 Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs. Unknown status NCT02698969 Phase 4 Sugammadex;Neostigmine;Atropine;Rocuronium;Fentanyl;Propofol;Sevoflurane
21 A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
22 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed NCT02082678 Phase 4 Ondansetron;Placebo
23 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
24 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
25 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial Completed NCT00190957 Phase 4 Atomoxetine;placebo
26 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
27 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
28 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Completed NCT01749215 Phase 4 Topiramate;placebo
29 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
30 Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism Completed NCT00115037 Phase 4 Naltrexone;placebo
31 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
32 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
33 Timing of Smoking Intervention in Alcohol Treatment Completed NCT00000444 Phase 4 nicotine replacement patch
34 Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study Completed NCT00620750 Phase 4 Extended release injectable naltrexone (Vivitrol)
35 SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis Completed NCT02504931 Phase 4 Sertraline;Placebo
36 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
37 Combined Pharmacotherapy in Depressed Alcoholics Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
38 The Treatment of Late Life Major Depression Complication by Alcohol Completed NCT00018824 Phase 4 NALTREXONE;Placebo
39 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
40 Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder Completed NCT01377168 Phase 4 oral naltrexone;Placebo pill
41 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
42 Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment Completed NCT02197598 Phase 4 nalmefene
43 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
44 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
45 Etiology and Treatment of Alcohol Dependence Completed NCT00000442 Phase 4 naltrexone (Revia)
46 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
47 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
48 Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
49 Targeted Naltrexone for Early Problem Drinkers Completed NCT00000455 Phase 4 naltrexone
50 Nalmefene in Nicotine and Alcohol Dependence Completed NCT00000437 Phase 4 Naltrexone Tablet and Nicotine Patch;Naltrexone Tablet and Placebo Patch;Placebo Tablet and Nicotine Patch;Placebo Tablet and Placebo Patch

Search NIH Clinical Center for Alcohol Use Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Disulfiram

Cochrane evidence based reviews: alcoholism

Sources

Genetic Tests for Alcohol Use Disorder

About this section
Sources

Anatomical Context for Alcohol Use Disorder

About this section

MalaCards organs/tissues related to Alcohol Use Disorder:

41
Liver, Brain, Testes, Heart, Bone, Pancreas, Lung
Sources

Publications for Alcohol Use Disorder

About this section

Articles related to Alcohol Use Disorder:

(show top 50) (show all 17582)
# Title Authors PMID Year
1
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. 9 38
20153935 2010
2
The opioid systems--panacea and nemesis. 9 38
20494127 2010
3
Validation of a headspace solid-phase microextraction-GC-MS/MS for the determination of ethyl glucuronide in hair according to forensic guidelines. 9 38
20061100 2010
4
Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. 9 38
19943812 2010
5
Brief motivational interviewing for DWI recidivists who abuse alcohol and are not participating in DWI intervention: a randomized controlled trial. 9 38
19930236 2010
6
RNA interference against aldehyde dehydrogenase-2: development of tools for alcohol research. 9 38
19251111 2009
7
[Association of the functional serotonin transporter promoter polymorphism (5-HTTLPR) with externalizing and internalizing aggressivity and alcohol abuse]. 9 38
19331786 2008
8
[Acute and chronic alcohol abuse and work]. 9 38
19288791 2008
9
Effectiveness of the CAGE questionnaire, gamma-glutamyltransferase and mean corpuscular volume of red blood cells as markers for alcohol-related problems in the workplace. 9 38
18337017 2008
10
The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. 9 38
18061976 2008
11
[The concentration of sialylated glycoproteins in the sera of alcohol dependent men]. 9 38
18293845 2007
12
Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. 9 38
17412797 2007
13
Biomarkers in alcoholism. 9 38
17045579 2007
14
Ethnicity and gamma-glutamyltransferase in men and women with alcohol use disorders. 9 38
17098749 2007
15
Obesity and the clinical use of serum GGT activity as a marker of heavy drinking. 9 38
17763184 2007
16
Genetic and environmental influences on the development of alcoholism: resilience vs. risk. 9 38
17347351 2006
17
Argininosuccinate lyase deficiency (ASL) and carbohydrate-deficient transferrin (CDT): experience with four independent CDT analysis methods--misleading results given by the %CDT TIA assay. 9 38
16808909 2006
18
[Alcohol abuse as a risk factor for ARDS]. 9 38
17176845 2006
19
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. 9 38
16945079 2006
20
[New and traditional laboratory markers of alcohol abuse in hospitalized alcohol dependent men]. 9 38
17037822 2006
21
Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. 9 38
16314872 2006
22
[New methods for the determination of transferrin isoforms in the diagnostics of alcohol abuse]. 9 38
16489296 2006
23
gamma-Glutamyltransferase is a promising biomarker for cardiovascular risk. 9 38
16891060 2006
24
[Depression of serum esterase and lipoprotein lipase activities in acute and longitudinal actions of ethanol]. 9 38
16739925 2006
25
Differential susceptibility of transferrin glycoforms to chymotrypsin: a proteomics approach to the detection of carbohydrate-deficient transferrin. 9 38
16331960 2005
26
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 9 38
16385229 2005
27
Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. 9 38
16215269 2005
28
Cytochrome P450 2E1 high activity polymorphism in alcohol abuse and end-organ disease. 9 38
16425414 2005
29
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. 9 38
15773422 2005
30
[Assessment of the usefulness of combination of selected clinical and demographic parameters in prediction of the severity of liver fibrosis in patients with chronic hepatitis C]. 9 38
16190546 2005
31
Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. 9 38
15772792 2005
32
Serum sialic acid and gamma-glutamyltransferase levels in alcohol-dependent individuals. 9 38
15639592 2004
33
Multicenter validation study of the %CDT TIA kit in alcohol abuse and alcohol dependence. 9 38
15365303 2004
34
[Iron overload disease: recent findings]. 9 38
15529941 2004
35
Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. 9 38
15164086 2004
36
Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. 9 38
15084894 2004
37
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 9 38
15040041 2004
38
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. 9 38
15288384 2004
39
Polymorphisms of the dopamine D2 receptor, serotonin transporter, and GABA(A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans. 9 38
15066703 2004
40
Use of biomarkers for alcohol use disorders in clinical practice. 9 38
14984245 2003
41
[Study on the relationship between smoking, alcohol intake and hyperlipidemia in fishermen]. 9 38
14761628 2003
42
Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. 9 38
12967770 2003
43
Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. 9 38
12774316 2003
44
Recognition of alcohol and substance abuse. 9 38
12722853 2003
45
The effects of ethanol on the glycosylation of human transferrin. 9 38
12626412 2003
46
Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. 9 38
12737448 2003
47
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 9 38
11704927 2001
48
A 2-year follow-up of 120 Swedish female alcoholics treated early in their drinking career: prediction of drinking outcome. 9 38
11707633 2001
49
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. 9 38
11513189 2001
50
Examination of a CYP2E1 repeat polymorphism in a monkey model of alcohol abuse. 9 38
11505041 2001
Sources

Variations for Alcohol Use Disorder

About this section
Sources

Expression for Alcohol Use Disorder

About this section
Search GEO for disease gene expression data for Alcohol Use Disorder.
Sources

Pathways for Alcohol Use Disorder

About this section

Pathways related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.48 HTR2A GRM5 GRIN2B GABRA2 GABBR1 DRD3
2
Circadian entrainment 37
Show member pathways
 12.91 GRM5 GRIN2B GABBR1 DRD3 DRD2 DRD1
3
Transmission across Chemical Synapses 66
Show member pathways
 12.88 SLC6A4 GRM5 GRIN2B GABRA2 GABBR1 ALDH2
4
Drug metabolism - cytochrome P450 37
Show member pathways
 12.71 CYP2E1 ALDH9A1 ALDH2 ADH1C ADH1B
5
GABAergic synapse 37
Show member pathways
 12.44 GRM5 GABRA2 GABBR1 DRD1
6
Dopamine-DARPP32 Feedback onto cAMP Pathway 64
12.23 GRIN2B DRD3 DRD2 DRD1
8
Long-term potentiation 37
Show member pathways
 12.05 GRM5 GRIN2B DRD2 DRD1
9
cAMP signaling pathway 37
12.05 GRIN2B GABBR1 DRD2 DRD1 BDNF
10
Taste transduction 37
Show member pathways
 11.9 HTR3A GRM5 GABRA2 GABBR1
11
Serotonergic synapse 37
11.86 SLC6A4 HTR3A HTR2A
12
Amphetamine addiction 37
Show member pathways
 11.85 GRIN2B DRD2 DRD1 BDNF
13
Monoamine GPCRs 1
Show member pathways
 11.8 HTR2A DRD3 DRD2 DRD1
14
superpathway of tryptophan utilization 1
Show member pathways
 11.77 CYP2E1 ALDH9A1 ALDH2 ADH1B
15
Gap junction 37
11.61 HTR2A GRM5 DRD2 DRD1
16
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.56 TF SLC6A4 HTR3A HTR2A BDNF
17
Cyclophosphamide Pathway, Pharmacodynamics 61
Show member pathways
 11.16 ALDH2 ADH1C ADH1B
18
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
11.06 SLC6A4 HTR3A HTR2A
19
DARPP-32 Phosphorylation 65
10.92 DRD3 DRD2 DRD1
20
GPCRs, Class C Metabotropic glutamate, pheromone 1
10.82 GRM5 GABBR1
21
noradrenaline and adrenaline degradation 1
Show member pathways
 10.79 ALDH2 ADH1B
22
Abacavir Pathway, Pharmacokinetics/Pharmacodynamics 61
10.72 ADH1C ADH1B
23
Synaptic Neurotransmission Pathways: GABAergic Inhibition 65
10.66 GRM5 GABRA2 GABBR1
24
acetone degradation I (to methylglyoxal) 1
Show member pathways
 10.63 CYP2E1 ADH1B
25
Microglia Activation During Neuroinflammation: Steady-State Microglia 65
10.58 GABBR1 DRD2 DRD1 BDNF
26
ethanol degradation II 1
Show member pathways
 10.51 CYP2E1 ALDH2 ADH1B
Sources

GO Terms for Alcohol Use Disorder

About this section

Cellular components related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.88 HTR2A GABRA2 GABBR1 DRD2 BDNF
2 integral component of plasma membrane GO:0005887 9.85 SLC6A4 HTR3A HTR2A GRM5 GRIN2B GABRA2
3 neuron projection GO:0043005 9.83 SLC6A4 HTR3A GRM5 GRIN2B GABRA2
4 postsynaptic membrane GO:0045211 9.8 HTR3A GRIN2B GABRA2 GABBR1
5 axon GO:0030424 9.77 HTR3A HTR2A GABRA2 DRD2 BDNF
6 glutamatergic synapse GO:0098978 9.72 HTR3A HTR2A DRD3 DRD2 DRD1
7 endocytic vesicle GO:0030139 9.63 TF DRD3 DRD2
8 GABA-ergic synapse GO:0098982 9.56 GABBR1 DRD3 DRD2 DRD1
9 dopaminergic synapse GO:0098691 9.51 DRD3 DRD2
10 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 HTR3A HTR2A DRD2 DRD1
11 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 HTR3A HTR2A DRD2 DRD1
12 plasma membrane GO:0005886 10.22 SLC6A4 HTR3A HTR2A GRM5 GRIN2B GGT1

Biological processes related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.95 HTR3A HTR2A GRM5 GRIN2B GABRA2
2 response to drug GO:0042493 9.85 SLC6A4 HTR2A DRD3 DRD2 DRD1 CYP2E1
3 locomotory behavior GO:0007626 9.84 GRM5 DRD3 DRD2 DRD1
4 excitatory postsynaptic potential GO:0060079 9.81 HTR3A GRIN2B DRD2
5 learning GO:0007612 9.81 GRM5 DRD3 DRD1
6 memory GO:0007613 9.81 SLC6A4 HTR2A DRD1 BDNF
7 synapse assembly GO:0007416 9.8 DRD2 DRD1 BDNF
8 learning or memory GO:0007611 9.79 GRM5 GRIN2B DRD3
9 regulation of synaptic vesicle exocytosis GO:2000300 9.78 HTR2A DRD2 DRD1
10 visual learning GO:0008542 9.77 DRD3 DRD2 DRD1
11 response to amphetamine GO:0001975 9.73 DRD3 DRD2 DRD1
12 temperature homeostasis GO:0001659 9.7 HTR2A DRD2 DRD1
13 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.69 DRD3 DRD2
14 negative regulation of protein secretion GO:0050709 9.68 DRD3 DRD2
15 striatum development GO:0021756 9.68 DRD2 DRD1
16 positive regulation of renal sodium excretion GO:0035815 9.68 DRD3 DRD2
17 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A4 ALDH9A1
18 grooming behavior GO:0007625 9.67 DRD2 DRD1
19 G protein-coupled receptor internalization GO:0002031 9.67 DRD3 DRD2
20 synaptic transmission, dopaminergic GO:0001963 9.67 DRD3 DRD2 DRD1
21 peristalsis GO:0030432 9.66 DRD2 DRD1
22 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.66 DRD3 DRD2
23 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.65 DRD3 DRD1
24 serotonin receptor signaling pathway GO:0007210 9.65 HTR3A HTR2A
25 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.65 GRM5 DRD2
26 dopamine receptor signaling pathway GO:0007212 9.65 DRD3 DRD2 DRD1
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.64 HTR2A DRD2
28 prepulse inhibition GO:0060134 9.63 DRD3 DRD2 DRD1
29 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.62 DRD2 DRD1
30 regulation of postsynaptic membrane potential GO:0060078 9.62 HTR3A GRM5 GABRA2 GABBR1
31 cerebral cortex GABAergic interneuron migration GO:0021853 9.61 DRD2 DRD1
32 dopamine metabolic process GO:0042417 9.61 DRD3 DRD2 DRD1
33 negative regulation of dopamine receptor signaling pathway GO:0060160 9.59 DRD3 DRD2
34 response to histamine GO:0034776 9.58 DRD3 DRD2
35 regulation of locomotion involved in locomotory behavior GO:0090325 9.58 DRD3 DRD2
36 ethanol oxidation GO:0006069 9.58 ALDH2 ADH1C ADH1B
37 acid secretion GO:0046717 9.57 DRD3 DRD2
38 response to cocaine GO:0042220 9.56 HTR3A DRD3 DRD2 DRD1
39 response to ethanol GO:0045471 9.55 HTR3A GRIN2B DRD3 DRD2 CYP2E1
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.13 DRD3 DRD2 DRD1
41 behavioral response to cocaine GO:0048148 8.92 HTR2A DRD3 DRD2 DRD1
42 signal transduction GO:0007165 10.27 HTR3A HTR2A GRM5 GABRA2 GABBR1 DRD3

Molecular functions related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 CYP2E1 ALDH9A1 ALDH2 ADH1C ADH1B
2 drug binding GO:0008144 9.58 HTR2A DRD3 DRD2
3 adrenergic receptor activity GO:0004935 9.48 DRD3 DRD2
4 aldehyde dehydrogenase (NAD) activity GO:0004029 9.43 ALDH9A1 ALDH2
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD3 DRD2
6 dopamine binding GO:0035240 9.33 DRD3 DRD2 DRD1
7 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.32 ADH1C ADH1B
8 glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity GO:0043878 9.26 ALDH9A1 ALDH2
9 serotonin binding GO:0051378 9.13 SLC6A4 HTR3A HTR2A
10 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD3 DRD2 DRD1
Sources

Sources for Alcohol Use Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....